

RESPONSE UNDER 37 CFR 1.116
 EXPEDITED PROCEDURE
 EXAMINING GROUP 1623

PATENT

Rev 07/05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
 CENTRAL FAX CENTER

OCT 12 2006

In re application : Mitchell P. Fink et al.
 Application No. : 10/659,063
 Filed : September 10, 2003
 Confirmation No. : 3827
 For : EXTRACELLULAR NAD+ AND CADPR AS POTENT
 ANTI-INFLAMMATORY AGENTS
 Examiner : Henry, Michael C.
 Attorney's Docket : UPITT-008XX

TC Art Unit: 1623

Do
 not
 Enter

M.C.H.
 11/20/06

By: Holliday C. Heine
 Holliday C. Heine, Ph.D.
 Registration No. 34,346
 Attorney for Applicant(s)

AMENDMENT PURSUANT TO 37 C.F.R. §1.116

Via Facsimile
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

In response to the final Office Action dated June 12, 2006,
 in the above-identified patent application, please amend the
 claims as follows.

WEINTRAUB, SCHNECKEIN,
 CACHTAIN & LEBOVITZ LLP
 TEL. (617) 453-2390
 FAX. (617) 451-0113